Last reviewed · How we verify

systemic metronidazole and amoxicillin

The Forsyth Institute · Phase 3 active Small molecule

A combination antibiotic therapy that kills anaerobic bacteria and gram-positive cocci through DNA damage and cell wall inhibition, respectively.

A combination antibiotic therapy that kills anaerobic bacteria and gram-positive cocci through DNA damage and cell wall inhibition, respectively. Used for Periodontal disease / aggressive periodontitis, Oral anaerobic infections.

At a glance

Generic namesystemic metronidazole and amoxicillin
SponsorThe Forsyth Institute
Drug classAntibiotic combination
TargetBacterial DNA (metronidazole); bacterial cell wall peptidoglycan (amoxicillin)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Periodontal Disease
PhasePhase 3

Mechanism of action

Metronidazole is a nitroimidazole that generates reactive oxygen species to damage bacterial DNA and is effective against anaerobic organisms. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins. Together, this combination provides broad-spectrum coverage against oral anaerobes and facultative anaerobes commonly associated with periodontal disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: